{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T11:16:46Z","timestamp":1783250206644,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003484","name":"Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The kallikrein-kinin system (KKS) is involved in many physiological and pathophysiological processes and is assumed to be connected to the development of clinical symptoms of angioedema or COVID-19, among other diseases. However, despite its diverse role in the regulation of physiological and pathophysiological functions, knowledge about the KKS in vivo remains limited. The short half-lives of kinins, their low abundance and structural similarities and the artificial generation of the kinin bradykinin greatly hinder reliable and accurate determination of kinin levels in plasma. To address these issues, a sensitive LC-MS\/MS platform for the comprehensive and simultaneous determination of the four active kinins bradykinin, kallidin, des-Arg(9)-bradykinin and des-Arg(10)-kallidin and their major metabolites bradykinin 2-9, bradykinin 1-7 and bradykinin 1-5 was developed. This platform was validated according to the bioanalytical guideline of the US Food and Drug Administration regarding linearity, accuracy, precision, sensitivity, carry-over, recovery, parallelism, matrix effects and stability in plasma of healthy volunteers. The validated platform encompassed a broad calibration curve range from 2.0\u201315.3\u00a0pg\/mL (depending on the kinin) up to 1000\u00a0pg\/mL, covering the expected concentrations in disease states. No source-dependent matrix effects were identified, and suitable stability of the analytes in plasma was observed. The applicability of the developed platform was proven by the determination of endogenous levels in healthy volunteers, whose plasma kinin levels were successfully detected in the low pg\/mL range. The established platform facilitates the investigation of kinin-mediated diseases (e.g. angioedema, COVID-19) and enables the assessment of the impact of altered enzyme activities on the formation or degradation of kinins.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00216-021-03231-9","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T22:02:48Z","timestamp":1615413768000},"page":"2971-2984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeted LC-MS\/MS platform for the comprehensive determination of peptides in the kallikrein-kinin system"],"prefix":"10.1007","volume":"413","author":[{"given":"Tanja","family":"Gangnus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-9937","authenticated-orcid":false,"given":"Bjoern B.","family":"Burckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"3231_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/1354750X.2013.787544","volume":"18","author":"E Kashuba","year":"2013","unstructured":"Kashuba E, Bailey J, Allsup D, Cawkwell L. The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers. 2013;18:279\u201396. https:\/\/doi.org\/10.3109\/1354750X.2013.787544.","journal-title":"Biomarkers."},{"key":"3231_CR2","doi-asserted-by":"publisher","first-page":"R897","DOI":"10.1152\/ajpregu.2000.278.4.R897","volume":"278","author":"AM Duncan","year":"2000","unstructured":"Duncan AM, Kladis A, Jennings GL, Dart AM, Esler M, Campbell DJ. Kinins in humans. Am J Physiol Regul Integr Comp Physiol. 2000;278:R897\u2013904. https:\/\/doi.org\/10.1152\/ajpregu.2000.278.4.R897.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3231_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jaci.2018.06.032","volume":"142","author":"SA Hubser","year":"2018","unstructured":"Hubser SA, Kohm K, Wei S, Yu C, Nian H, Grabert R, et al. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2018;142:1636\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.032.","journal-title":"J Allergy Clin Immunol"},{"key":"3231_CR4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/S0140-6736(08)60595-4","volume":"371","author":"KF Chung","year":"2008","unstructured":"Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371:1364\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60595-4.","journal-title":"Lancet"},{"key":"3231_CR5","doi-asserted-by":"publisher","unstructured":"Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.59177.","DOI":"10.7554\/eLife.59177"},{"key":"3231_CR6","doi-asserted-by":"publisher","unstructured":"Campbell DJ. Towards understanding the kallikrein-kinin system: insights from measurements of kinin peptides. Braz J Med Biol Res. 2000:665\u201377. https:\/\/doi.org\/10.1590\/s0100-879x2000000600008.","DOI":"10.1590\/s0100-879x2000000600008"},{"key":"3231_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1517\/14728222.4.2.127","volume":"4","author":"PG McLean","year":"2005","unstructured":"McLean PG, Perretti M, Ahluwalia A. Kinin B 1 receptors as novel anti-inflammatory targets. Emerg Ther Targets. 2005;4:127\u201341. https:\/\/doi.org\/10.1517\/14728222.4.2.127.","journal-title":"Emerg Ther Targets"},{"key":"3231_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0162-3109(99)00133-2","volume":"43","author":"C Blais","year":"1999","unstructured":"Blais C, Rouleau J-L, Brown NJ, Lepage Y, Spence D, Munoz C, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology. 1999;43:293\u2013302.","journal-title":"Immunopharmacology."},{"key":"3231_CR9","doi-asserted-by":"publisher","first-page":"109886","DOI":"10.1016\/j.mehy.2020.109886","volume":"143","author":"LAD Nicolau","year":"2020","unstructured":"Nicolau LAD, Magalh\u00e3es PJC, Vale ML. What would S\u00e9rgio Ferreira say to your physician in this war against COVID-19: how about kallikrein\/kinin system? Med Hypotheses. 2020;143:109886. https:\/\/doi.org\/10.1016\/j.mehy.2020.109886.","journal-title":"Med Hypotheses"},{"key":"3231_CR10","doi-asserted-by":"publisher","unstructured":"van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JWM, de Mast Q, Br\u00fcggemann RJ, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.57555.","DOI":"10.7554\/eLife.57555"},{"key":"3231_CR11","doi-asserted-by":"publisher","unstructured":"Kaplan AP, Ghebrehiwet B. Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin Immunol. 2020. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.025.","DOI":"10.1016\/j.jaci.2020.10.025"},{"key":"3231_CR12","doi-asserted-by":"publisher","first-page":"H275","DOI":"10.1152\/ajpheart.2001.281.1.H275","volume":"281","author":"M Cyr","year":"2001","unstructured":"Cyr M, Lepage Y, Blais C, Gervais N, Cugno M, Rouleau J-L, et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol. 2001;281:H275\u201383. https:\/\/doi.org\/10.1152\/ajpheart.2001.281.1.H275.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3231_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/B0-12-370879-6\/00209-X","volume-title":"Encyclopedia of respiratory medicine","author":"J Eddleston","year":"2006","unstructured":"Eddleston J, Christiansen SC, Zuraw BL. Kinins and neuropeptides | bradykinin. In: Laurent GJ, Shapiro SD, editors. Encyclopedia of respiratory medicine. Amsterdam: Elsevier; 2006. p. 502\u20136. https:\/\/doi.org\/10.1016\/B0-12-370879-6\/00209-X."},{"key":"3231_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1160\/TH13-03-0258","volume":"110","author":"J Bj\u00f6rkqvist","year":"2013","unstructured":"Bj\u00f6rkqvist J, J\u00e4ms\u00e4 A, Renn\u00e9 T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost. 2013;110:399\u2013407. https:\/\/doi.org\/10.1160\/TH13-03-0258.","journal-title":"Thromb Haemost"},{"key":"3231_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/abio.1995.1311","volume":"228","author":"U Hilgenfeldt","year":"1995","unstructured":"Hilgenfeldt U, Linke R, Riester U, K\u00f6nig W, Breipohl G. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal Biochem. 1995;228:35\u201341. https:\/\/doi.org\/10.1006\/abio.1995.1311.","journal-title":"Anal Biochem"},{"key":"3231_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1042\/cs0870567","volume":"87","author":"A Pellacani","year":"1994","unstructured":"Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567\u201374.","journal-title":"Clin Sci"},{"key":"3231_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0009-8981(82)90191-7","volume":"125","author":"MD Nielsen","year":"1982","unstructured":"Nielsen MD, Nielsen F, Kappelgaard AM, Giese J. Double-antibody solid-phase radioimmunoassay for blood bradykinin. Clin Chim Acta. 1982;125:145\u201356. https:\/\/doi.org\/10.1016\/0009-8981(82)90191-7.","journal-title":"Clin Chim Acta"},{"key":"3231_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ab.2009.07.021","volume":"394","author":"M Lortie","year":"2009","unstructured":"Lortie M, Bark S, Blantz R, Hook V. Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry. Anal Biochem. 2009;394:164\u201370. https:\/\/doi.org\/10.1016\/j.ab.2009.07.021.","journal-title":"Anal Biochem"},{"key":"3231_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cca.2019.02.023","volume":"493","author":"M Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m M, Valkonen M, Tohmola N, Renkonen R, Strandin T, Vaheri A, et al. Plasma bradykinin concentrations during septic shock determined by a novel LC-MS\/MS assay. Clin Chim Acta. 2019;493:20\u20134. https:\/\/doi.org\/10.1016\/j.cca.2019.02.023.","journal-title":"Clin Chim Acta"},{"key":"3231_CR20","unstructured":"Lame ME, Chambers EE, Fountain KJ. An improved SPE-LC-MS\/MS method for the quantification of bradykinin in human plasma using the ionKey\/MS system. 2016;Application note 720004945EN:8\u201315."},{"key":"3231_CR21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jchromb.2010.01.011","volume":"878","author":"I van den Broek","year":"2010","unstructured":"van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:590\u2013602. https:\/\/doi.org\/10.1016\/j.jchromb.2010.01.011.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3231_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jchromb.2013.12.033","volume":"947-948","author":"KF Seip","year":"2014","unstructured":"Seip KF, Bjerknes KC, Johansen HT, Nielsen EW, Landr\u00f8 L, Reubsaet L. Bradykinin analysis revived--a validated method for determination of its stable metabolite in whole blood by LC-MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;947-948:139\u201344. https:\/\/doi.org\/10.1016\/j.jchromb.2013.12.033.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3231_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/abio.2001.5073","volume":"292","author":"LJ Murphey","year":"2001","unstructured":"Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem. 2001;292:87\u201393. https:\/\/doi.org\/10.1006\/abio.2001.5073.","journal-title":"Anal Biochem"},{"key":"3231_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(97)09137-X.","journal-title":"Lancet"},{"key":"3231_CR25","unstructured":"U.S. Food and Drug Administration. Bioanalytical method validation. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"3231_CR26","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2). 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"3231_CR27","unstructured":"Enzo Life Sciences, Inc. Bradykinin ELISA kit, ADI-900-206. https:\/\/www.enzolifesciences.com\/ADI-900-206\/bradykinin-elisa-kit\/. Accessed 3 Nov 2020."},{"key":"3231_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.HYP.21.2.155","volume":"21","author":"DJ Campbell","year":"1993","unstructured":"Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993;21:155\u201365. https:\/\/doi.org\/10.1161\/01.HYP.21.2.155.","journal-title":"Hypertension."},{"key":"3231_CR29","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1021\/pr100395s","volume":"9","author":"AWJ van Winden","year":"2010","unstructured":"van Winden AWJ, van den Broek I, Gast M-CW, Engwegen JYMN, Sparidans RW, van Dulken EJ, et al. Serum degradome markers for the detection of breast cancer. J Proteome Res. 2010;9:3781\u20138. https:\/\/doi.org\/10.1021\/pr100395s.","journal-title":"J Proteome Res"},{"key":"3231_CR30","doi-asserted-by":"publisher","first-page":"121134","DOI":"10.1016\/j.talanta.2020.121134","volume":"218","author":"T Gangnus","year":"2020","unstructured":"Gangnus T, Burckhardt BB. Improving sensitivity for the targeted LC-MS\/MS analysis of the peptide bradykinin using a design of experiments approach. Talanta. 2020;218:121134. https:\/\/doi.org\/10.1016\/j.talanta.2020.121134.","journal-title":"Talanta."},{"key":"3231_CR31","doi-asserted-by":"publisher","unstructured":"Gangnus T, Burckhardt BB. Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-82191-7.","DOI":"10.1038\/s41598-021-82191-7"},{"key":"3231_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.4155\/bio-2018-0105","volume":"10","author":"A Wakamatsu","year":"2018","unstructured":"Wakamatsu A, Ochiai S, Suzuki E, Yokota Y, Ochiai M, Kotani Y, et al. Proposed selection strategy of surrogate matrix to quantify endogenous substances by Japan Bioanalysis Forum DG2015-15. Bioanalysis. 2018;10:1349\u201360. https:\/\/doi.org\/10.4155\/bio-2018-0105.","journal-title":"Bioanalysis."},{"key":"3231_CR33","unstructured":"Lame ME. Development of a quantitative SPE LC-MS\/MS assay for bradykinin in human plasma. 2013. http:\/\/www.waters.com\/waters\/library.htm?cid=511436&lid=134773810&locale=101. Accessed 13 Apr 2020."},{"key":"3231_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40560-017-0228-x","volume":"5","author":"H Nicola","year":"2017","unstructured":"Nicola H. The role of contact system in septic shock: the next target? An overview of the current evidence. J Intensive Care. 2017;5:31. https:\/\/doi.org\/10.1186\/s40560-017-0228-x.","journal-title":"J Intensive Care"},{"key":"3231_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1567-5769(02)00162-5","volume":"3","author":"M Cugno","year":"2003","unstructured":"Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311\u20137. https:\/\/doi.org\/10.1016\/S1567-5769(02)00162-5.","journal-title":"Int Immunopharmacol"},{"key":"3231_CR36","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"key":"3231_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","volume":"506","author":"G Lippi","year":"2020","unstructured":"Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145\u20138. https:\/\/doi.org\/10.1016\/j.cca.2020.03.022.","journal-title":"Clin Chim Acta"},{"key":"3231_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-642-83737-1_6","volume-title":"Update in intensive care and emergency medicine","author":"SE Kinsey","year":"1989","unstructured":"Kinsey SE, Machin SJ. The role of the contact system in the pathophysiology of ARDS. In: Vincent JL, editor. Update in intensive care and emergency medicine. Berlin: Springer-Verlag; 1989. p. 39\u201347. https:\/\/doi.org\/10.1007\/978-3-642-83737-1_6."},{"key":"3231_CR39","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1096\/fj.202000967","volume":"34","author":"JA Roche","year":"2020","unstructured":"Roche JA, Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020;34:7265\u20139. https:\/\/doi.org\/10.1096\/fj.202000967.","journal-title":"FASEB J"},{"key":"3231_CR40","unstructured":"Piccoli SP, Sauer JM, Writing Group, Critical Path Institute. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. 2019."},{"key":"3231_CR41","unstructured":"ICH M10 Guideline on bioanalytical method validation step 2b. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf."}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-021-03231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00216-021-03231-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-021-03231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:06:31Z","timestamp":1618365991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00216-021-03231-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3231"],"URL":"https:\/\/doi.org\/10.1007\/s00216-021-03231-9","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave written informed consent prior to their enrolment. The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of the medical faculty at the Heinrich Heine University (study number: 6112).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}